In this video, Anna C Pavlick, DO, MBA, co-director of the Melanoma Program at NYU Langone Health’s Perlmutter Cancer Center, discusses whether targeted therapy or immunotherapy should be administered first in patients with melanoma with BRAF mutations.

Learn more by clicking here.